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Abstract
Reliable antibody based-assays are needed to evaluate the immunogenicity of current vaccines, 
impact of altered dosing schemes or of new vaccine formulations. An ideal assay platform would 
allow multiplex type-specific detection with minimal sample requirement.
We used the Meso Scale Discovery (MSD) electrochemiluminescence based detection platform to 
develop a multiplex direct virus-like particle (VLP) ELISA to detect antibodies to HPV 6, 11, 16, 
and 18 with a protocol developed for detection using the SI 6000 imager (M4ELISA). MSD 
prepared the plates in the 7-spot/well format, using the purified VLPs (4 spots) and PBS + BSA 
pH 7.4 (3 blank spots). Three-point titrations and the parallel line method were used to calculate 
antibody levels. Dynamic range, precision, and stability of pre-printed plates were determined 
using a panel of previously characterized sera. Cut-off values using children’s sera were 
established using 99% RLU limits based on the 4-parameter Johnson Su best fit curve. Results of 
the M4ELISA were compared to competitive Luminex Immunoassay (cLIA) on n = 4454 sera 
from a predominantly unvaccinated cohort.
Using a VLP coating concentration of 80 μg/ml with BSA provided the most robust RLU signal 
for all types. The dynamic range of the assay was about 1000 fold, with assay variability under 
25% for each of the four vaccine types. Long-term stability of the plates extended to about 7 
months from the time plates was received in the laboratory after printing. There was moderate 
agreement (κ = 0.38–0.54) between M4ELISA and cLIA, with antibody detection for each of the 4 
types more frequent with M4ELISA. Quantitative analysis however showed a good correlation 
between concordant samples by both assays (ρ ≥ 0.6). The MSD platform shows promise for 
simultaneous quantitation of the antibody responses to four HPV vaccine types in a high-
throughput manner.
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Human papillomavirus (HPV) serology has been used as a measure of lifetime exposure to 
HPV. In HPV vaccine trials, serology was used to identify naïve individuals, to monitor the 
response to vaccination and for immunobridging (Schiller et al., 2012). In the absence of 
immune correlates of protection, non-inferiority of the immune response has been used in 
evaluating altered dosing schedules and new vaccine formulations.
Neutralizing assays, such as the pseudovirion based neutralizing assays (PBNA), are the 
gold standard for HPV serology as protection is believed to be due to neutralizing 
antibodies. These neutralizing assays are labor and time intensive, so most large scale 
studies use other antibody detection assays. As the major immune response is to neutralizing 
epitopes, these assays generally correlate with PBNA. Both direct ELISA [with 
conformationally intact L1 viral-like particles (VLP) as antigen] and competitive Luminex 
Immunoassay (cLIA) [a bead-based liquid array (Luminex Corporation, Austin, TX) with 
labeled type-specific neutralizing monoclonal antibody that competes with test serum for 
binding] have been used in HPV vaccine trials (Schiller and Lowy, 2009). Inherent 
differences in the type of antibody response measured, lack of standardized reagents as well 
as lack of uniform methods to establish cut-off values have plagued comparisons between 
these assays.
Multiplexed assays are increasingly needed as current vaccines target 4 types, and a 
candidate 9-valent vaccine is under review. Multiplexing allows for use of reduced sample 
volume and increased throughput for large studies. The two most widely used platforms for 
multiplex assays are the bead-based liquid arrays (Luminex) and electrochemiluminescent 
multi-spot assays. Meso Scale Discovery (MSD, Rockville, MD) uses 
electrochemiluminesence technology which lends itself to a large dynamic range for the 
assay. The spots are printed in an array within each well of the carbon electrode multi-spot 
plates. The small area of each spot requires less L1-VLP capture reagent. Conformationally 
intact L1-VLPs are the key to the assay, and conserving this key reagent reduces cost of 
production and the time for the extensive quality control (QC) that is required. Because the 
capture reagent binds directly to the plate, the assay is similar to a traditional single-plex 
ELISA and competition between analytes is reduced. The current plate formats offered by 
MSD allow for multiplexing 4, 7 or 10 analytes in a single well. The equipment does not 
require any fluidics as it is based on images of the electrochemical signal captured by the 
CCD camera with fast read times (about 70 s/plate). We developed a direct L1-VLP ELISA 
using the MSD platform to simultaneously detect antibodies to HPV 6,11,16 and 18 and 
performed studies to validate the performance in terms of reproducibility, linear range, 
lower limits of detection, stability of antigen and agreement with cLIA on a cohort of 
samples from the general population of the US prior to vaccine introduction.
2. Materials and methods
2.1. VLP production and purification
HPV L1/L2 VLPs were produced in Human Embryonic Kidney cells 293TT, and purified 
using Optiprep™ density gradient (Sigma-Aldrich, St. Louis, MO) as described (Pastrana et 
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al., 2004). Plasmid constructs for HPV 6, 11, 16 and 18 were obtained as a gift from J. 
Schiller, National Cancer Institute, Bethesda, MD. Optiprep™ was removed from the VLP 
preparations using manual gravity-flow based agarose gel filtration. Each VLP fraction was 
stored at −80 °C with a small aliquot saved for downstream quality analysis. Protein 
determinations were done using Coomasie Plus Protein Assay (Thermo Scientific, Waltham, 
MA). The integrity and quality of the VLPs in each fraction were determined using type-
specific monoclonal antibodies (Gift of Dr. Neil Christensen, Pennsylvania State University, 
USA) that recognize a conformational epitope on intact VLPs (WHO HPV Labnet, 2009). 
VLP fractions with reactivity equal or higher to the laboratory reference VLP stock were 
pooled to make a new lot of VLP stock. New VLP stock was aliquoted and stored at −80 °C. 
One aliquot of pooled VLP was again verified for uniformity of shape and size using 
transmission electron microscopy (TEM) as well as by conformation specific ELISA for 
reactivity equal or higher to the laboratory reference VLP stock. The fully verified pooled 
VLP stock was considered qualified for plate coating.
2.2. Selection of assay parameters
HPV 16 single-plex assays were used to evaluate the type of MSD plate, blocking buffer, 
antigen coating concentration, secondary antibody concentration and incubation times. 
Single-plex plate printing was performed in-house. A 30 μl aliquot of HPV 16 VLPs diluted 
in phosphate buffered saline (PBS) (pH7.4) was added to each well of single-spot plate 
being evaluated and incubated at 4 °C overnight prior to use for testing. ELISA was 
performed using known control sera with protocol shown in Section 2.4. Evaluation criteria 
were comparison of the relative light units (RLU) of positive, negative and blank wells.
Additional parameters, including buffer for VLP antigens (Dulbecco’s-Phosphate Buffered 
Saline (D-PBS) (pH7.4) + 0.5MNaCl with or without Optiprep™), VLP coating 
concentrations of 20–80 μg/ml, and agents for stabilizing VLP antigen (with or without 
bovine serum albumin [BSA] or proprietary stabilizer agent) were evaluated on multiplex 
plates printed by MSD in 7-spot format. HPV 6, 11, 16, and 18 VLPs occupied 4 spots and 
PBS-BSA alone was used in the remaining 3 spots. Frozen VLP aliquots were sent to MSD 
on dry-ice where they were stored at −80 °C and thawed prior to printing. The proprietary 
MSD printing protocol includes QC for spotting accuracy. Plates were shipped to CDC on 
ice packs within 3–5 days of printing and stored at 4 °C until used for testing. A panel of 16 
to 19 residual individual sera that were high, low, and negative in reactivity to the four VLP 
types based on cLIA (Gift from Merck, Inc.) was used to evaluate the assay parameters 
using washing and detection protocol as given in Section 2.4.
2.3. Serum samples and controls
For validation experiments, a heat-inactivated pooled serum sample positive for HPV 6, 11, 
16 and 18 (Gift from Merck, Inc.) was used as the reference. This sample was calibrated to 
the HPV16 International Standard (05–134, National Institute for Biological Standards and 
Controls [NIBSC], Potters Bar, UK) to determine international units (IU)/ml, whereas 
arbitrary units/ml (AU/ml) were used for the other HPV types. Pooled serum that was high, 
low and/or negative in reactivity to the different HPV types were used as controls for assay 
stability. Residual sera from U.S. population-based samples collected between 2005 and 
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2006, prior to widespread vaccine introduction (n = 4454) that had been previously tested by 
cLIA (Pharmaceutical Product Development LLC (PPD), Wilmington, NC) were used to 
compare the two assays. A subset of these samples (n = 100) was used for reproducibility 
testing across different plate lots and to determine the appropriate dilution series for sample 
testing. Serum from children (n = 49, gift of Dr. Joakim Dillner, Lund University, Sweden) 
were used to determine cut-off values (COV) for RLUs for each type.
2.4. MSD 4-plex L1 VLP ELISA (M4ELISA) protocol
Serial 3.16 fold dilutions of serum were prepared with assay diluent [1% ECL™ Blocking 
Agent (GE Healthcare Biosciences, Piscataway, NJ) in 1X PBST (PBS—0.1% Tween 20)], 
starting with 1:10 dilution or 1:100 dilution and higher. For each sample, a minimum of 3 
dilutions were tested. Serial dilution was performed by Janus® automated liquid handling 
workstation (PerkinElmer, Waltham, MA). All other steps were performed manually. Plates 
were blocked for 1 h with 5% ECL™ Blocking Agent in 1X PBST at room temperature (24 
°C ± 2), 150 μl per well, on a lab rotator set at 650 rpm. All incubations for subsequent steps 
were at 37 °C for 1 h with shaking at 650 rpm. After removal of the blocking agent, 25 μl of 
sample per well was added and the plate incubated. After each incubation plates were 
washed 4 times with 150 μl per well of 1X PBST using an automated plate washer 
(ELx405VRS, Biotek, Winooski, VT). 25 μl of biotin-labeled mouse anti-human IgG (Fc 
specific) (Biotrend Chemicals LLC, Destin, FL) at 1 μg/ml in assay diluent, followed by 25 
μl of Streptavidin-Sulfo Tag™(MSD) (1:500 dilution in assay diluent) was added to each 
well in subsequent steps. 150 μl of 1X Read Buffer T (MSD) was added to each well and the 
plate was immediately read on the Sector Imager 6000 (MSD) (read time: 70 s/plate). RLU 
for each spot was exported to Microsoft Excel.
2.4.1. Calculations—Net RLU was calculated by subtracting RLU blank from RLU of 
each VLP spot in the same well. Net RLUs were used in determination of dynamic range 
and determination of antibody concentrations with the parallel line method (PLL) as 
described in the WHO HPV Labnet Manual (Grabowska et al., 2002; WHO HPV Labnet, 
2009). Samples with RLU below COV that failed PLL conditions were assigned a zero titer. 
The RLU COV for each HPV type was determined for each plate lot based on RLUs of 
1:100 dilution of children’s sera. The RLU distribution was not normal and best fit a 4-
parameter Johnson Su distribution (JOHNSON, 1949). The improved fit to the Johnson Su 
distribution more than compensated for the two extra parameters needed beyond the normal 
distribution, as determined by parsimony metrics such as the Akaike Information Criterion 
(AIC) (Akaike, 1974) and the Bayes Information Criterion (BIC) (Schwarz, 1978). The 
Lognormal distribution was not a candidate for this data since, for the unexposed sera, a 
significant portion of the values were <0 after background subtraction. The RLU at the 99th 
percentile probability distribution (approximately equal to average RLU + 2.33 Standard 
Deviations (SD) if the data were normally distributed) was used as the COV unless 
otherwise specified. When noted, the RLU at the 99.87 percentile (approximately equal to 
average RLU + 3 SD) was used as an alternative COV.
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2.5. Establishing assay performance characteristics
2.5.1. Dynamic range—Serial dilutions of high titer sera and plasma from vaccinated 
individuals, diluted from 1:10 to 1:3.14 × 106, were used to determine the linear dynamic 
range of the net RLU for three lots of plates. The minimum detection signal was based on 
average + 3SD over the background signal using only sample diluent for a given VLP type. 
The maximum signal was set at 1 × 106 RLU, the manufacturer’s designated upper limit for 
reproducible signal.
2.5.2. Assay variability—Inter-assay coefficient of variation (CV) for quantifiable 
antibody concentrations within plate lot was determined for two plate lots printed with 
different VLP preparations using 17–20 serum samples tested in three runs per plate lot, 
calculated as median CV for both lots. Lot-to-lot inter-assay coefficient of variation was also 
determined using 11–22 serum samples tested in one run per lot for three plate lots printed 
with the same VLP preparation and 3 plate lots printed with different VLP preparations. All 
assays were conducted by the same operator. Inter-operator coefficient of variation was 
calculated between two operators based on one run on the same plate lot with 23 samples. 
Intra-assay coefficient of variation was calculated for two operators based on one sample 
tested on 10–12 plates of the same lot over 4–6 days.
2.5.3. Assay reproducibility—Samples from a mostly unvaccinated cohort were selected 
based on results of cLIA to include high, low and negative reactivity to the HPV 6, 11, 16 
and 18 (n = 100). Samples were tested on two plate lots using a different starting dilution 
(1:10 or 1:100). Kappa scores were used to evaluate agreement of positive and negative 
results when tested at different dilutions and different plate lots.
2.5.4. Assay stability—A set of 19 serum samples was assayed once a month on a plate 
from same lot stored at 4 °C. One lot was tested over a 12 month period and a second lot 
was tested for 5 months of storage. Time in months was based on the date of receipt in the 
laboratory not the date of printing. Average fold difference in antibody levels was calculated 
at each month compared to the first run.
2.6. Assay comparison with cLIA
Final assay parameters established for the M4ELISA were validated by testing 4454 residual 
samples previously tested with cLIA (Dias, 2005). M4ELISA assay antibody levels 
(expressed as IU/ml or AU/ml) were compared with cLIA results (mMU/ml or IU/ml). For 
HPV16, 1 IU/ml = 11.8 mMU/ml (Personal Communication, PPD). Qualitative concordance 
between the assays was evaluated using the Cohen’s kappa score as well as positive and 
negative percent agreements. McNemar’s test was performed to identify the test most likely 
to be positive for antibody detection. Geometric mean concentrations (GMCs) were 
calculated by type and assay restricted to type-specific positive samples. Except for HPV16, 
GMCs between assays cannot be compared due to arbitrary units. For HPV16, GMC 
comparisons were restricted to samples positive in both cLIA and M4ELISA. Spearman’s 
correlation was calculated for all samples as well as for concordant quantitatifiable 
concentrations between assays. All statistical analyses were conducted on SPSS ver 21.0 
software (IBM, NY) and GraphPad Prism ver 5.0 (La Jolla, CA). Correlation graphs were 
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created using the ggplot2 package in the R program (http://www.R-project.org) (R Core 
Team, 2014; Wickham, 2009). For graphing purposes only, all values below the detection 
limit for cLIA were assigned a value of 5 for HPV types 6, 11, 18 and 0.5 for HPV16.
3. Results
3.1. Assay performance characteristics
Table 1 summarizes the set of conditions evaluated and selected as the final assay 
conditions. The dynamic range of the assay was about 1000 fold as evidenced by the linear 
response seen across 7 dilution steps of a high titer vaccinated serum sample for each HPV 
type (Fig. 1). The range was consistent over three printed plate lots, with the lower limit of 
detection based on wells containing only sample diluent ranging from 350 to 650 RLU 
depending on plate lot.
The median inter-assay variability was less than 20% for all VLP types irrespective of the 
plate and reagent lots. Fig. 2 illustrates the inter-assay CVs observed within a plate lot across 
a range of antibody concentrations measured. Inter-assay variability within the same plate 
lot was—HPV6 (8.7%), HPV11 (8.9%), HPV16 (7.5%) and HPV 18 (15.8%) (Fig. 2A). The 
variability between two plate lots with the same VLP preparation was 12.8% for HPV 6, 
10.3% for HPV11, 8.3% for HPV16 to 7.9% for HPV 18 (Fig. 2B). Variability among three 
plate lots with different VLP preparations was slightly higher; 15.8% for HPV6, 14.5% for 
HPV11, 16.9% for HPV16 and 17.4% for HPV18 (Fig. 2C). Intra-assay variability ranged 
from 2.9 to 4.8% for operator 1 and 3.5 to 6.7% for operator 2. Inter-operator variability was 
not extensively evaluated, but median CVs ranged from 5.5 to 13.8% for the four types.
Antibody levels for HPV types did not vary more than 2-fold over 5 months for both plate 
lots evaluated during storage at 4 °C. For the lot evaluated through 12 months of storage, 
HPV6, 11 and 16 levels remained stable, whereas results for HPV18 varied after month 5 
(Fig. 3).
The quantitative correlation of antibody levels between samples tested at 1:10 and 1:100 
starting dilutions on two plate lots was r2 > 0.90 for HPV6, 11, 16 and r2 > 0.87 for HPV18. 
The kappa score for qualitative agreement between the two lots was 0.8–0.9 for each of the 
types, with neither lot significantly differing in detection even though different starting 
dilutions were used (McNemar’s p-value >0.6 for all types). Type-specificity of the 
M4ELISA was confirmed by testing HPV16 international standard and HPV18 candidate 
international standard, which were positive only for the respective type and negative for the 
other three types.
3.2. Assay comparison with cLIA
The overall agreement between the assays ranged from 86.3 to 91.5% for the four types. 
Positive percent agreement between the two assays ranged from 41.1 to 61.7%. The kappa 
statistic showed poor to fair agreement between the assays, with the lowest score for HPV18 
(κ = 0.38) (Table 2).
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The maximum HPV16 antibody concentration was 141.5 and 142.8 IU/ml for cLIA and 
M4ELISA respectively. There was no significant difference for HPV16 GMCs calculated 
for concordant samples (6.2 IU/ml cLIA [95% CI 5.7–6.8] vs 6.7 IU/ml MSD [95% CI 5.8–
7.7] (p = 0.23) and HPV16 GMCs were within two-fold if all positive samples by each assay 
were included: 5.7 IU/ml [95% CI 5.2–6.2 IU/ml] for cLIA positive (n = 401) and 2.6 IU/ml 
[95% CI 2.4–2.9 IU/ml] for M4ELISA positive (n = 796). Correlations of antibody levels for 
all samples were ρ = 0.53 for HPV6, 0.37 for HPV11, 0.46 for HPV16 and 0.34 for HPV18 
assays (Fig. 4). For concordant samples between each assay, the correlations were ρ = 0.59 
HPV6, 0.56 for HPV11, 0.62 for HPV16 and 0.69 for HPV18.
As shown in Table 2, more samples were seropositive by M4ELISA than cLIA (HPV6—
22.9% vs 12.8%; HPV11—11.6% vs 4.5%; HPV16—17.8% vs 9.0%; HPV18—11.1% vs 
3.3%; p-value <0.001 for all types). The proportions of cLIA negative M4ELISA positive 
were 11.8% HPV 6, 7.8% HPV11, 10.0% HPV16 and 8.2% HPV18, and the proportions of 
cLIA positive M4ELISA negative were 1.8% HPV6, 0.7% HPV11, 1.2% HPV16, and 0.3% 
HPV18 (McNemar’s p < 0.000001 for all types).
Raising the M4ELISA RLU COV to the 99.87-percentile raised the agreement to κ = 0.6–
0.7 for all types. The positive percent agreement was 72.1% for HPV6, 64.4% HPV11, 
68.3%HPV16, and 65.2% HPV18. McNemar’s differed by type indicating that M4ELISA 
was more likely to be positive than cLIA for HPV11 and 18 p < 0.002; but not for HPV6 p = 
0.34 and HPV 16 p = 0.07. The proportion of cLIA negative M4ELISA positive samples 
decreased, 3.3% HPV6, 2.2% HPV11, 3.3% HPV16 and 1.6% HPV18.
4. Discussion
This report describes a multiplex ELISA based on the traditional direct L1-VLP ELISA 
plate format using MSD electrochemiluminescence platform with multi-spot printing to 
simultaneously detect antibody responses to HPV 6, 11, 16, and 18, the 4 types in the 
quadrivalent HPV vaccine. The M4ELISA was characterized by large dynamic range for 
each type (~1000 fold), low background, and plate read times of 70 s. Inter-assay variability 
as measured by median lot-to-lot CV with same or different VLP preparations was less than 
20% for all four types, a value within acceptable limits for multiplexed assays (Marchese et 
al., 2009; Opalka et al., 2003).
We used results of cLIA in an unvaccinated cohort to verify type-specificity and provide 
overall comparison to the M4ELISA. It is recognized that direct ELISA and cLIA will not 
be completely concordant due to differences in their design. ELISA detects IgG binding to 
all epitopes on VLPs which could include both neutralizing and non-neutralizing epitopes 
and cLIA detects antibodies of any Ig class that bind to one neutralizing epitope (Schiller 
and Lowy, 2009). The M4ELISA showed moderate agreement with cLIA for HPV6 and 16 
(κ = 0.54 and 0.53 respectively) and fair for HPV 11 and 18 (κ = 0.44 and 0.38 
respectively). For all types M4ELISA detected ~2–3 fold more positive samples than cLIA, 
and this affected both concordance and correlation between the assays. These findings are 
similar to results observed by other studies comparing VLP-ELISA to cLIA in unvaccinated 
cohorts with κ ranging from 0.29 to 0.66 (Lin et al., 2013; Scherpenisse et al., 2013; 
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Wentzensen et al., 2011). Most of the discrepant results are near the lower limit of the 
M4ELISA. Raising the COV for RLUs in M4ELISA from the 99-percentile to the 99.87-
percentile (equivalent to + 3SD) improved overall positive agreement and resulted in similar 
seropositivity rates between the two assays for all four types. Similar results were observed 
by Safaeian et al. (2012), where positive percent agreement between HPV16 VLP-ELISA 
and cLIA increased from 49% to 78% with higher COV for ELISA to allow for comparison 
of the two assay formats.
Determination of cut-off value for HPV serology is difficult as true negatives are hard to 
determine, leading to varied ways of calculating assay cut-offs. cLIA cut-offs were 
determined using a clinical sensitivity/specificity algorithm on adult sera, which ensured 
high specificity of detection at the cost of sensitivity (Dias et al., 2005; Opalka et al., 2003). 
However, we believe that the 99% RLU limits on children’s sera better reflects the 
capability of the M4ELISA for detection of antibodies to natural exposure.
The design of the MSD multi-spot wells reduces background noise as each spot forms its 
own circuit measuring electrochemiluminescent signal bound only to the spot and not to the 
walls of the microwell. The separate binding surface also reduces competition between 
antibodies and detection reagent. The low background could contribute to improved 
detection of antibody response in naturally infected populations, where the antibody levels 
are low. The Spearman correlation of antibody levels between cLIA and M4ELISA was 
moderate for each type and ranged between 0.34 and 0.53. For HPV16 and HPV18, 
correlation was similar to those reported between cLIA and another ELISA platform in 
unvaccinated population (Wentzensen et al., 2011). Differences between the two assays in 
high antibody level situations, such as post vaccination, can be anticipated to be smaller. 
With the exception of HPV16, a direct comparison of GMTs between the assays was not 
possible. The maximum antibody concentration for HPV16 was in agreement between cLIA 
and M4ELISA (141.5 and 142.8 IU/ml respectively) as was the GMT for HPV 16 
concordant samples (6.2 and 6.7 IU/ml). As the cohort was mostly unvaccinated, only the 
response to natural exposure was measured. In other reports, GMTs are significantly higher 
after vaccination than those after natural infection (Romanowski et al., 2009; Schiller et al., 
2012). The ability to make this direct comparison between assays for HPV16 highlights the 
importance of incorporating International Standards into HPV serology assays.
It is recognized that QC of the VLP production is essential for maintaining type-specificity 
of the reaction (Ferguson et al., 2009). Our results (data not shown) indicate that VLPs in 
Optiprep™ Gradient Media could be used to coat single-plex MSD plates, but lead to 
inconsistent antigen printing in 7-spot MSD plates. Removing Optiprep™ resulted in 
acceptable consistency of antigen printing. We hypothesize that the viscous Optiprep™ 
media could be interfering with the automated delivery lines designed to deliver very low 
volumes (nanoliter range) of liquid on each spot. Infrequent random irregularities in 
spotting, independent of HPV type, were detected in each plate lot as evidenced by 1 out of 
3 dilutions of the sample showing low RLU for only one spot within the well. When this 
occurred, sample was re-tested.
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Most published L1-VLP ELISAs specify preparation of plates just prior to use. Multi-spot 
printing requires sending antigen to the manufacturer for printing. Stability for at least a 
week was required in order for the assay to be used in any study, but for large cohort testing 
use of a single lot of reagents would be ideal. Therefore, validating stability of the MSD-
printed plates was important. The combination of BSA with VLP concentration of 80 μg/ml 
allowed for robust detection of antibody for up to twelve months using the same preparation 
of VLP on printed plates. The effect of BSA on stabilization of protein and enzymes has 
been well-documented, but the mechanism of action is not clear. It is thought to increase 
hydrophobic interactions with the protein, thus preventing denaturation (Chang and 
Mahoney, 1995; Finn et al., 2012).
This is the first study to compare ELISA and cLIA for HPV6 and 11, providing an 
estimation of antibody response to natural exposure by both assay platforms. We have 
shown that the multiplexed M4ELISA is reproducible, sensitive, and amenable to high-
throughput testing. The assay advantages include the low antigen requirement, rapid reading 
times, and simplicity of scanner maintenance compared with liquid array platform. The 
multi-well options for MSD plates include a 10-spot format, suggesting that the current 
assay could be expanded to include additional HPV types required for testing antibody 
response to the candidate 9-valent HPV vaccine. The assay also has limitations. The 
antigens have to be printed by the manufacturer and the plates stored until use. The spot 
drop-out, noted above, required more repeat testing than would normally occur. Several 
factors need to be evaluated further such as inter-operator variability and intra-assay 
variation within a range of antibody concentrations.
“The findings and conclusions in this report are those of the author(s) and do not 
necessarily represent the views of the funding agency.”
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Dynamic range of M4ELISA for HPV6, 11, 16 and 18.
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Coefficient of variation. A—Within plate lot (17–20 serum samples tested on two plate lots 
with three runs per plate lot); B—Lot-to-lot CV (11–22 serum samples tested on three plate 
lots printed with the same VLP preparation with one run per plate lot); and C—Lot-to-lot 
CV (11–22 serum samples tested on three plate lots printed with different VLP preparations 
with one run per plate lot).
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Stability of printed assay plates stored at 4 °C for 12 months.
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Correlation of antibody levels between M4ELISA and cLIA for all samples.
Panicker et al. Page 14

























Panicker et al. Page 15
Table 1
Assay conditions evaluated for optimization of M4ELISA.
Parameter Variations tested Selected condition
Evaluated in single-plex assay
MSD plate Standard, high-bind Standard
Blocking buffer/assay diluent Superblock (ThermoFisher, Rockford, IL)
ECL blocking agent (GE Healthcare Biosciences, Pittsburgh, PA)
ECL blocking agent
Secondary antibody concentration 0.5, 1 μg/ml 1 μg/ml
Secondary antibody incubation time 1 h, 2 h 1 h
Evaluated in multiplex assay
VLP storage solution Optiprep
Dulbecco’s-PBS + 0.5 M NaCl
Dulbecco’s-PBS + 0.5 M NaCl
VLP coating concentration 20, 40, 80 μg/ml 80 μg/ml
BSA co-spotting With BSA
Without BSA
With BSA
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